scispace - formally typeset
Journal ArticleDOI

Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion.

Reads0
Chats0
TLDR
Recent developments of BCSC-mediated resistance to tamoxifen and the contributions of those demonstrated molecular factors/pathways to BCSC expansion during the emergency of tamoxIFen resistance are discussed.
Abstract
Estrogen receptor-alpha positive (ER + ) breast cancer constitutes 70-75% of the disease incidence Tamoxifen has been the basis of endocrine therapy for patients with ER + breast cancer for more than three decades The treatment reduces the annual mortality rate of breast cancer by 31%, and remains the most effective targeted cancer therapy However, approximately one-third of patients treated with adjuvant tamoxifen suffer from aggressive recurrent disease Resistance to tamoxifen, thus, remains a major challenge in providing effective treatments for these patients In an effort to overcome the resistance, intensive research has been conducted to understand the underlying mechanisms; this has resulted in the identification of complex factors/pathways contributing to tamoxifen resistance, including modulations of the ERsignaling, upregulation of a set of growth factor receptor networks (HER2, EGFR, FGFR, and IGF1R), alterations of the PI3K-PTEN/AKT/mTOR pathway, and an elevation of the NF-κB signaling Despite these advances, our understanding of the acquired resistance remains fragmented and there is a lack of a platform to integrate these diversified molecular factors/ pathways into a cohesive mechanistic model Nonetheless, at the cellular level, it is becoming increasingly recongnized that cancer stem cells (CSCs) are key in driving cancer metastasis and therapy resistance Likewise, evidence is emerging for the critical contributions of breast cancer stem cells (BCSCs) to tamoxifen resistance In this review, we will discuss these recent developments of BCSC-mediated resistance to tamoxifen and the contributions of those demonstrated molecular factors/pathways to BCSC expansion during the emergency of tamoxifen resistance

read more

Citations
More filters
Journal ArticleDOI

Endocrine resistance in breast cancer--An overview and update.

TL;DR: This review explores the basic mechanisms of resistance to endocrine therapies, concluding with some new insights from systems biology approaches further implicating autophagy and the UPR in detail, and a brief discussion of exciting new avenues and future prospects.
Journal ArticleDOI

circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer

TL;DR: Hsa_circ_0025202 served an anti-oncogenic role in HR-positive breast cancer, and it could be exploited as a novel marker for tamoxifen-resistant breast cancer.
Journal ArticleDOI

Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

TL;DR: It is demonstrated that ER+ breast cancers contain two CAF subtypes defined by CD146 expression, which suggest that CAF composition contributes to treatment response and patient outcomes in ER+, and should be considered a target for drug development.
Journal ArticleDOI

LncRNA UCA1 in anti-cancer drug resistance.

TL;DR: The potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors, is highlighted and its potential in future clinical applications is discussed.
Journal ArticleDOI

Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.

TL;DR: The expression of UCA1 positively correlated with the pathological grade and mortality of breast cancer patients, moreover, expressions of U CA1 was increased significantly in the tamoxifen-resistant cell lines compared with the wild type parental cells, which highlights the pivotal role of Uca1-Wnt/β-catenin signaling pathway in theTamoxIFen resistance in breast cancer.
Related Papers (5)

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

O. Abe, +412 more
- 14 May 2005 -